Immune Checkpoint Inhibitor Clinical Trial
Official title:
Endocrine-related Adverse Events Caused by Immune Checkpoint Inhibitors
Immune checkpoint inhibitor (ICI) includes agents that block cytotoxic T-cell-associated antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death protein ligand 1 (PD-L1). Since the FDA-approval of the CTLA-4 inhibitor ipilimumab in 2011, ICI drugs have emerged as a powerful new tool in the treatment for several advanced cancers. Now indications for ICI have expanded dramatically due to their efficacy and include a wide array of cancer types. However, the administration of ICI, whereas, carry the risk of developing immune-related adverse events (irAEs) and may lead to serious and even fatal events. Endocrine dysfunctions are among the most common irAEs that have been reported in clinical trials with ICI, including thyroid dysfunction, hypopituitarism, primary adrenal insufficiency (PAI) and insulin-deficient diabetes (ICI-DM). However, it is difficult to acquire a complete picture of irAEs from randomized controlled trials (RCTs) due to limitations in the study design and realistic practicalities.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05848011 -
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
| Recruiting |
NCT06197581 -
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
|
N/A | |
| Recruiting |
NCT05576961 -
Safety and Efficacy of RX-af01 Combined With PD-1 Antibody
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04659382 -
Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer
|
Phase 2 | |
| Withdrawn |
NCT05653531 -
Clinical Significance of Hepatic Biomarkers in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
|
N/A | |
| Completed |
NCT04470440 -
Thyroid Dysfunction and Nivolumab Reponse in NSCLC
|
||
| Recruiting |
NCT05554432 -
Development of an EORTC Immune Checkpoint Inhibitor-specific Quality of Life Item List: Phase 1 & 2
|
||
| Recruiting |
NCT05863260 -
Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer
|
||
| Recruiting |
NCT06259162 -
LAG3 Expression in Triple Negative Breast Cancer
|
N/A | |
| Not yet recruiting |
NCT05810402 -
Liver Cancer and Immunotherapy in the Liquid Biopsy Era
|
N/A | |
| Recruiting |
NCT05385185 -
Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05311566 -
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
|
Phase 2 | |
| Recruiting |
NCT06227728 -
Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
|
||
| Recruiting |
NCT05799898 -
Fast-Track Cardiovascular Assessment for Suspicion of Cardiovascular Events on Immunecheckpoint Inhibitors
|
||
| Recruiting |
NCT04414969 -
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04891016 -
Toripalimab Plus FLOT in Locally Advanced Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT04419441 -
Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma
|
||
| Not yet recruiting |
NCT05915481 -
Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06007274 -
Troponin to Detect Major Cardiovasculaire Advserse Events on Immune Checkpoint Inhibitors
|
||
| Active, not recruiting |
NCT05383716 -
Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy
|
Phase 2 |